Overview

Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors

Status:
Completed
Trial end date:
2008-09-03
Target enrollment:
Participant gender:
Summary
This trial was a Phase I/II, non-randomized, open label, multi-center study, following a sequential 2-part design.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Everolimus
Imatinib Mesylate
Sirolimus